Runt-related transcription factor 2 (RUNX2)

Runt-related transcription factor 2, commonly abbreviated as RUNX2, is a master regulator of osteoblast and chondrocyte differentiation and is essential for bone formation and maintenance. It is a DNA-binding transcription factor belonging to the RUNX family, containing a Runt domain, and is known for regulating the expression of multiple downstream genes critical for skeletal development[2][5][8]. RUNX2 controls osteoblast commitment, proliferation, chondrocyte maturation, and cell cycle progression, and additionally interacts with molecular pathways involving FGFs, Wnts, and other skeletal regulators. Its importance is highlighted by its involvement in congenital bone disorders such as cleidocranial dysplasia and certain cancers, notably osteosarcoma. While not a classic drug target like a receptor or enzyme, modulation of RUNX2 activity remains a key therapeutic strategy in emerging bone disease research[7][3][1].

Other names

Core-binding factor subunit alpha-1CBF-alpha-1RUNX2AML3

Most acting molecules (e.g., adriamycin) modify RUNX2 expression/activity indirectly by modulating associated pathways (e.g., DNA damage, histone acetylation); future therapeutic concepts aim at direct inhibition of its transcriptional activity or post-translational modification [7][1]